Article

67 views
KEY POINTS ERK inhibitors are the new class of drugs in development for resistant cancers Merck’s ERK inhibitor, MK-8353 in ...
Authentic, Ad-free Reporting
High-quality, Exclusive Content
Original Market Research Reports
Original Resources & Databases
Global Surveys & Guidelines
Lowest Subscription Pricing

Healthcare News You Won't Read Elsewhere

Most up-to-date information, original and in-depth reviews, full-length exclusive market reports and forecasts, full-access to the smart knowledge base centres, useful resources and databases.

Access articles & resources worth up to $4000.

KEY POINTS ERK inhibitors are the new class of drugs in development for resistant cancers Merck’s ERK inhibitor, MK-8353 in ...

You have read of your 8 free articles this month.

Subscribe to
Medgenera All-Access

Enjoy unlimited access to all contents, resources, exclusive market research reports, databases, surveys and many more features by subscribing to Medgenera All-Access.

Access articles & resources worth up to US $4, 000 per month.

Authentic, Ad-free Reporting
High-quality, Exclusive Content
Original Market Research Reports
Original Resources & Databases
Global Surveys & Guidelines
Lowest Subscription Pricing

Healthcare News You Won't Read Elsewhere

Most up-to-date information, original and in-depth reviews, full-length exclusive market reports and forecasts, full-access to the smart knowledge base centres, useful resources and databases.

Access articles & resources worth up to $4000.

More in DRUG TRIAL


DRUG TRIAL

This New Cancer Drug Signifies ‘No Return of a Rare Blood Cancer’

AstraZeneca’s promising blood cancer drug, moxetumomab pasudotox has shown tumor shrinkage in 75 percent patients with hairy cell leukemia- a rare and chronic form of blood cancer.

DRUG TRIAL

15 Promising New Cancer Drugs in Late-Stage Clinical Development (2018)

Read about the most promising oncology drug candidates present in the pharmaceutical companies’ pipeline in 2018. The potential drugs with novel mechanisms are in their late-stage of clinical development to treat diverse types of cancers.

BRIEFING

Novel EGFR Lung Cancer Drug, Dacomitinib Gains FDA Priority Review

The understanding of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) has been evolved over years. TKIs are found ...

DRUG TRIAL

New Potential Immuno-Oncology Drug for Blood Cancer Received Orphan Drug Status

Chinese biotech, Maxinovel Pharma’s immuno-oncology drug candidate- MAX-40279 received Orphan Drug designation from the US FDA for the treatment of ...

Most Popular


GROW

7 New Ideas to Start a Healthcare Business in India (2018)

Highlights Herein, we are proposing the seven new healthcare business ideas in India in 2018 which are based on our ...

NEWLY PUBLISHED

Pharma Patents: Can India Reward Incremental Innovation?

Chandramouli Natarajan is an Associate Scientist, Ricon pharma LLC, Denville, USA. He has presented his opinion and views on the Pharmaceutical patents issues in India. This article is available for free to read and share.